Results 271 to 280 of about 287,634 (309)
Some of the next articles are maybe not open access.
Microchimerism and Systemic Sclerosis
International Archives of Allergy and Immunology, 2001Systemic sclerosis (SSc) is a connective tissue disease characterized by progressive fibrosis of the skin and internal organs. SSc is an immunologically mediated disease. A prominent immunological abnormality in SSc patients is the presence of circulating autoantibodies against a variety of nuclear proteins.
SCALETTI, CRISTINA +4 more
openaire +3 more sources
Systemic Sclerosis, Scleroderma
2006Abstract The scleroderma spectrum of disorders includes several diseases that have Raynaud’s phenomenon or skin sclerosis in common, comprising (1) localized cutaneous scleroderma; (2) systemic sclerosis (SSc)—the most important form of scleroderma—limited cutaneous SSc, diffuse cutaneous SSc, and overlap syndromes (with features of ...
Christopher P. Denton, Carol M. Black
openaire +1 more source
2009
Systemic sclerosis and its subtypes differ significantly from other diseases in rheumatology and clinical immunology, as the aberrant activation of the immune system does not result in an inflammation-driven destruction but in a progressive matrix synthesis, especially of the skin. Owing to the recently established networks in Germany (DNSS) as well as
openaire +2 more sources
Systemic sclerosis and its subtypes differ significantly from other diseases in rheumatology and clinical immunology, as the aberrant activation of the immune system does not result in an inflammation-driven destruction but in a progressive matrix synthesis, especially of the skin. Owing to the recently established networks in Germany (DNSS) as well as
openaire +2 more sources
Progressive Systemic Sclerosis
Annals of Internal Medicine, 1978Excerpt To the editor: Data in a recent article on Sjogren's syndrome in scleroderma by Cipoletti and associates (Ann Intern Med87:535-541, 1977) apparently differ enough from ours (1) to cite us i...
openaire +2 more sources
Systemic sclerosis and multiple sclerosis
Journal of Neurology, 1999[No abstract available]
SPADARO, Antonio +3 more
openaire +2 more sources
Progressive Systemic Sclerosis
Clinics in Rheumatic Diseases, 1983To date, largely because of convenience, therapeutic trials in progressive systemic sclerosis have been few and largely short-term retrospective single institution studies. For the future, there is a pressing need to expand efforts in this area to include: controlled, prospective studies with adequate numbers of patients employing, if necessary, a ...
openaire +2 more sources
Treatment of systemic sclerosis
Current Opinion in Rheumatology, 1991Systemic sclerosis is an extremely variable disease in its manifestations and consequently, treatment needs to be individualized depending on the specific problems that each patient has. Limited scleroderma patients have a prolonged duration of Raynaud's phenomenon and puffy fingers before they develop any skin thickening, digital ulcers or ...
openaire +3 more sources
Treatment of systemic sclerosis
Current Opinion in Rheumatology, 1993Guidelines for the conduct of clinical trials in progressive systemic sclerosis have been recommended to determine drug efficacy better. To date, the results of disease-modifying drugs in scleroderma have been disappointing. The treatment of esophagitis has been revolutionized by omeprazole.
openaire +3 more sources
Thinking outside the box: non-canonical targets in multiple sclerosis
Nature Reviews Drug Discovery, 2022Orhan Aktas, Tobias Ruck, Michael Roden
exaly